.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,767,901

« Back to Dashboard

Claims for Patent: 6,767,901

Title: Ciclesonide contained pharmaceutical composition for application to mucosa
Abstract:The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high ciclesonide retentivity and permeability to the submucosa or the blood at the mucosa.
Inventor(s): Nagano; Atsuhiro (Tokyo, JP), Nishibe; Yoshihisa (Yamaguchi, JP), Takanashi; Kazuya (Tokyo, JP)
Assignee: Altana Pharma AG (Constance, DE)
Application Number:10/110,629
Patent Claims: 1. An aqueous pharmaceutical composition for application to the mucosa, comprising one or more water-insoluble and/or water-low soluble substance, and ciclesonide, and having an osmotic pressure of 150 mOsm or less.

2. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 60 mOsm or less.

3. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 30 mOsm or less.

4. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said osmotic pressure is 10 mOsm or less.

5. The pharmaceutical composition for application to the mucosa according to claim 1, further comprising an osmotic pressure-controlling agent.

6. The pharmaceutical composition for application to the mucosa according to claim 5, wherein said osmotic pressure-controlling agent is a salt.

7. The pharmaceutical composition for application to the mucosa according to claim 6, wherein said osmotic pressure-controlling agent is sodium chloride.

8. The pharmaceutical composition for application to the mucosa according to claim 5, wherein said osmotic pressure-controlling agent is a water-soluble sugar.

9. The pharmaceutical composition for application to the mucosa according to claim 8, wherein said osmotic pressure-controlling agent is glucose.

10. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said water-insoluble and/or water-low soluble substance is a cellulose.

11. The pharmaceutical composition for application to the mucosa according to claim 10, wherein said cellulose is crystalline cellulose.

12. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said one or more water-insoluble and/or water-low soluble substance is present as solid particles in an aqueous medium.

13. The pharmaceutical composition for application to the mucosa according to claim 1, wherein said one or more water-insoluble and/or water-low soluble substance is dispersed as solid particles in an aqueous medium.

14. The pharmaceutical composition for application to the mucosa according to claim 1, further comprising a water-soluble polymer substance.

15. The pharmaceutical composition for application to the mucosa according to claim 14, wherein said water-soluble polymer is one or more selected from the group consisting of alginic acid, propylene glycol, pectin, low methoxyl pectin guar gum, gum arabic, carrageenan, methyl cellulose, carboxymethyl cellulose sodium, xanthan gum, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.

16. The pharmaceutical composition for application to the mucosa according to claim 14, wherein said water-soluble polymer is carboxymethyl cellulose sodium.

17. The pharmaceutical composition for application to the mucosa according to claim 14, wherein said water-soluble polymer is xanthan gum.

18. The pharmaceutical composition for application to the mucosa according to claim 15, wherein said water-soluble polymer is hydroxypropyl methyl cellulose.

19. The pharmaceutical composition for application to the mucosa according to claim 14, wherein the combination of said water-insoluble substance and water-soluble polymer is crystalline cellulose carmellose sodium.

20. The pharmaceutical composition for application to the mucosa according to claim 1, further comprising a surfactant.

21. The pharmaceutical composition for application to the mucosa according to claim 20, wherein said surfactant is polysorbate 80.

22. The pharmaceutical composition ion to the mucosa according to claim 1, mucosa is nasal mucosa.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc